Literature DB >> 35799075

Evaluation of the effects of duloxetine treatment on anterior segment parameters by optical coherence tomography.

Murat A Özer1, İlker F Sarı2, Hakan Koç3, Nurçe Ç Yavuz2, Serkan Özen3, Fazıl Kulaklı2.   

Abstract

PURPOSE: To evaluate the effects of Duloxetine on anterior segment parameters and intraocular pressure (IOP) in open angle eyes.
METHODS: 38 eyes of 38 patients with fibromyalgia who had open or wide open angles according to the Shaffer classification. Anterior segment optic coherence tomography was performed before and after (month 3) Duloxetine treatment. IOP, central corneal thickness (CCT), corneal endothelial cell density (CECD) and anterior chamber depth (ACD) were also recorded and evaluated.
RESULTS: No statistically significant difference was determined in IOP, CCT and CECD (p > 0.05). However, a statistically significant decrease was determined in both the temporal and nasal anterior chamber angle, angle opening distance, nasal trabecular-iris space area and ACD values between the baseline and month 3 (p < 0.001). DISCUSSION: We think that the short term use of Duloxetine does not lead to clinically significant changes despite their statistically significant effects on the anterior chamber parameters.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Anterior chamber angle; Anterior chamber depth; Duloxetine; Intraocular pressure; Optic coherence tomography

Year:  2022        PMID: 35799075     DOI: 10.1007/s10792-022-02396-1

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  15 in total

1.  Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults.

Authors:  Dallas P Seitz; Robert J Campbell; Chaim M Bell; Sudeep S Gill; Andrea Gruneir; Nathan Herrmann; Alice M Newman; Geoff Anderson; Paula A Rochon
Journal:  J Clin Psychopharmacol       Date:  2012-06       Impact factor: 3.153

2.  Acute angle closure glaucoma precipitated by olanzapine.

Authors:  Asaf Achiron; Uri Aviv; Liat Mendel; Zvia Burgansky-Eliash
Journal:  Int J Geriatr Psychiatry       Date:  2015-10       Impact factor: 3.485

Review 3.  Duloxetine: clinical pharmacokinetics and drug interactions.

Authors:  Mary Pat Knadler; Evelyn Lobo; Jill Chappell; Richard Bergstrom
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

4.  Chronic angle-closure glaucoma related to paroxetine treatment.

Authors:  M A Sierra-Rodriguez; F Saenz-Frances; E Santos-Bueso; J Garcia-Feijoo; J C Gonzelez-Romero
Journal:  Semin Ophthalmol       Date:  2013-04-29       Impact factor: 1.975

5.  Bilateral acute angle-closure glaucoma induced by duloxetine.

Authors:  Atum Mahmut; Vildan Tunc; Enes Demiryurek; Alagoz Gursoy
Journal:  Ideggyogy Sz       Date:  2017-09-30       Impact factor: 0.427

6.  How Does Usage of Serotonin Noradrenaline Reuptake Inhibitors Affect Intraocular Pressure in Depression Patients?

Authors:  Gamze Uçan Gündüz; Neslihan Parmak Yener; Oğuzhan Kılınçel; Cem Gündüz
Journal:  J Ocul Pharmacol Ther       Date:  2018-02-15       Impact factor: 2.671

Review 7.  Statistical approaches in published ophthalmic clinical science papers: a comparison to statistical practice two decades ago.

Authors:  Harrison G Zhang; Gui-Shuang Ying
Journal:  Br J Ophthalmol       Date:  2018-02-09       Impact factor: 4.638

8.  Association of Selective Serotonin Reuptake Inhibitor Use and Acute Angle-Closure Glaucoma.

Authors:  Hsin-Yi Chen; Cheng-Li Lin; Shih-Wei Lai; Chia-Hung Kao
Journal:  J Clin Psychiatry       Date:  2016-06       Impact factor: 4.384

Review 9.  SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms.

Authors:  Ciro Costagliola; Francesco Parmeggiani; Adolfo Sebastiani
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Probable Association of an Attack of Bilateral Acute Angle-Closure Glaucoma With Duloxetine.

Authors:  Amde Selassie Shifera; Anthony Leoncavallo; Mark Sherwood
Journal:  Ann Pharmacother       Date:  2014-04-14       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.